PAGES

News
About
Investors
Legal
Contact
Home

NEWSROOM

Press Releases

SCIENTURE Announces Executive Leadership Transition

Learn More

Press Releases

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.

Learn More

Press Releases

SCIENTURE announces manufacturing and supply chain readiness for Arbli™, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

Learn More

Press Releases

Scienture Holdings, Inc. Issues Annual Letter to Shareholders

Learn More

Press Releases

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization

Learn More

Press Releases

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days

Learn More

Press Releases

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.

Learn More

Press Releases

SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

Learn More

Event Calendar

Scienture Holdings, Inc. Announces Dr. Narasimhan Mani’s Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

Learn More

Press Releases

Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041

Learn More